Adenocarcinoma - Pipeline Review, H2 2013

Description:

Adenocarcinoma - Pipeline Review, H2 2013

Summary

Global Markets Direct's, 'Adenocarcinoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. Adenocarcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenocarcinoma.
- A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Adenocarcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Adenocarcinoma
Adenocarcinoma Therapeutics under Development by Companies
Adenocarcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Adenocarcinoma Therapeutics – Products under Development by Companies
Adenocarcinoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Adenocarcinoma Therapeutics Development
Boehringer Ingelheim GmbH
Sanofi-Aventis
Gilead Sciences, Inc.
Delcath Systems, Inc.
Lorus Therapeutics Inc
Peregrine Pharmaceuticals, Inc.
Morphotek, Inc.
MacroGenics, Inc.
Iconic Therapeutics, Inc.
Laboratorio Elea S.A.C.I.F. and A
Adenocarcinoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
LOR-1284 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Angiogenesis Agent 2C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bavituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hI-con1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irofulven - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-BCT-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Macrobeads - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP1-6D Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HM-30181-A + paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGARG-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GnRHm1-TT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MORAb-066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEI-DNA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Dendritic Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCT-1 Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenocarcinoma Therapeutics – Drug Profile Updates
Adenocarcinoma Therapeutics – Discontinued Products
Adenocarcinoma Therapeutics - Dormant Products
Adenocarcinoma – Product Development Milestones
Featured News & Press Releases
May 15, 2013: Boehringer Ingelheim To Present Five Abstracts For Afatinib At ASCO 2013
Jul 16, 2012: Peregrine Initiates Phase I Rectal Adenocarcinoma Investigator Sponsored Trial
Mar 15, 2012: Bio-Cancer Treatment International Obtains FDA Approval To Initiate Phase I Study Of Cancer Drug PEG-BCT-100
Dec 31, 2010: Authorization for the clinical trial “TherGAP”
Apr 20, 2007: Certification for the “TherGAP”
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Adenocarcinoma, H2 2013
Products under Development for Adenocarcinoma – Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Boehringer Ingelheim GmbH, H2 2013
Sanofi-Aventis, H2 2013
Gilead Sciences, Inc., H2 2013
Delcath Systems, Inc., H2 2013
Lorus Therapeutics Inc, H2 2013
Peregrine Pharmaceuticals, Inc., H2 2013
Morphotek, Inc., H2 2013
MacroGenics, Inc., H2 2013
Iconic Therapeutics, Inc., H2 2013
Laboratorio Elea S.A.C.I.F. and A, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Adenocarcinoma Therapeutics – Drug Profile Updates
Adenocarcinoma Therapeutics – Discontinued Products
Adenocarcinoma Therapeutics – Dormant Products
Adenocarcinoma Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Adenocarcinoma, H2 2013
Products under Development for Adenocarcinoma – Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 35

Ordering:  
Order Online -  http://www.researchandmarkets.com/reports/2615377/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adenocarcinoma - Pipeline Review, H2 2013
Web Address: http://www.researchandmarkets.com/reports/2615377/
Office Code: SCD23GP8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: ___________________________________________
Email Address: * _______________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _________________________________________________
Postal / Zip Code: _____________________________________
Country: ______________________________________________
Phone Number: _________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9853308331083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World